Atherosclerosis is now widely accepted as an active process involving a pathological vascular triad of vascular cellular activation, inflammation, and thrombosis. Several biomarkers show promise for risk prediction in high risk patients in large scale studies. Some are modified by statin therapy and may be targets for future therapeutic drug development whereas others identify high risk groups that benefit from specific treatments such as intensive statin therapy. Further understanding the role of different biomarkers will help better understand the pathophysiology of ACS as well as provide personalized medical care.
